Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and disposition study of [14C]PF-07054894
NL-OMON58683Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-07054894 in inflammatory bowel disease (IBD), sponsored by Pfizer. Started Jun 2025; status: completed.
02
Drugs
PF-07054894
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON58683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58683.